Niall Barron, director of the NICB, discusses the Institute’s research, which has included significant research into Chinese Hamster Ovary (CHO) cell engineering and the identification of micro-RNA mechanisms that can triple protein yields in some limited cases.
Could you please introduce the NICB to our global readers and the Institute’s key research foci?
If we can improve the yields and efficiency of cells by a significant margin, then the cost savings should be considerable
Eoin Vaughan, CEO of Mercury Engineering, and Dermot Gildea, Director of Life Sciences, highlight the key priorities of their exciting new Mercury 2021 strategy, the rationale behind their transition into…
David Adlam, Regional Manager of Ireland and South West UK, and Paul Morris, Strategic Account Manager for Life Sciences at Agility, discuss the company’s increased commitment to Ireland, their ongoing…
Jean Delaney, pharma leader and partner at PwC Ireland, discusses the evolution she has seen in the pharma market, and more broadly in Ireland, during her extensive career at PwC.…
The latest news from Irish pharma, including a big new R&D investment for Abbott; contact lens giant Bausch & Lomb’s EUR 90 million manufacturing investment; and a new report on…
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical company successfully listed on NASDAQ, raising over USD 30 million. Founded…
These are exciting times for Ipsen in Ireland, with plans to expand the company’s already significant API manufacturing footprint to deal with increasing global demand for its products. “Sales from…
See our Cookie Privacy Policy Here